Neoleukin Therapeutics Inc. (NLTX) is priced at $0.70 after the most recent trading session. At the very opening of the session, the stock price was $0.63 and reached a high price of $0.70, prior to closing the session it reached the value of $0.62. The stock touched a low price of $0.63.
Neoleukin Therapeutics Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $2.3200 on 04/04/22, with the lowest value was $0.3750 for the same time period, recorded on 11/17/22.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Neoleukin Therapeutics Inc. (NLTX) full year performance was -62.84%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Neoleukin Therapeutics Inc. shares are logging -69.88% during the 52-week period from high price, and 86.32% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $0.38 and $2.32.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 588019 for the day, which was evidently higher, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Neoleukin Therapeutics Inc. (NLTX) recorded performance in the market was 37.27%, having the revenues showcasing 46.02% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 34.05M, as it employees total of 79 workers.
Neoleukin Therapeutics Inc. (NLTX) in the eye of market guru’s
During the last month, 0 analysts gave the Neoleukin Therapeutics Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 0.5301, with a change in the price was noted +0.13. In a similar fashion, Neoleukin Therapeutics Inc. posted a movement of +22.58% for the period of last 100 days, recording 380,499 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for NLTX is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.
Neoleukin Therapeutics Inc. (NLTX): Stocks Technical analysis and Trends
Raw Stochastic average of Neoleukin Therapeutics Inc. in the period of last 50 days is set at 77.44%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 77.44%. In the last 20 days, the company’s Stochastic %K was 58.03% and its Stochastic %D was recorded 51.96%.
If we look into the earlier routines of Neoleukin Therapeutics Inc., multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be pessimistic, given the fact the metric is recording 37.27%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -28.70%, alongside a downfall of -62.84% for the period of the last 12 months. The shares increased approximately by -2.96% in the 7-day charts and went down by 20.47% in the period of the last 30 days. Common stock shares were driven by 46.02% during last recorded quarter.